• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Shire Dry Eye Treatment Set for Blockbuster Status, Says Report


November 05, 2015.

The global treatment market for dry eye syndrome will more than double in value from approximately $2.2 billion in 2014, to reach an estimated $4.6 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 7.9%, according to research and consulting firm GlobalData.

The company’s latest report states that this rise will be driven primarily by the introduction of novel drugs, most notably Shire’s lifitegrast, a first-in-class drug with anti-inflammatory benefits.

Furthermore, Catherine Daly, Ph.D., GlobalData’s Senior Analyst covering Neurology and Ophthalmology, says the paucity of dry eye syndrome treatments in the US and European markets will allow Shire to secure strong uptake and a sizable market share for lifitegrast.

Daly comments: “GlobalData expects that lifitegrast, which is anticipated to launch in the US in late 2016, will eventually reach peak sales of $1 billion across the nine major markets, earning the drug blockbuster status.

“Furthermore, Allergan’s blockbuster dry eye syndrome drug, Restasis, which generated an estimated $1.33 billion in US sales in 2014, is expected to launch in the European markets during the forecast period and will secure a sizable patient share.”

Catherine Daly will present a free webinar discussing the dry eye syndrome treatment market on Wednesday November 11 at 10am EST.

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024

Recent Videos
Related Content